SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Amgen Securities Litigation: UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE AMGEN INC. SECURITIES LITIGATION Civil Action No. 1:23-cv-02138 (JPC) (HJR) CLASS ACTION SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS THAT PURCHASED OR OTHERWISE ACQUIRED AMGEN INC. (“AMGEN” OR THE “COMPANY”) COMMON STOCK BETWEEN JULY 29, 2020 AND APRI.
Banco Santander S.A. grew its holdings in shares of Amgen Inc. (NASDAQ: AMGN) by 15.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,520 shares of the medical research company's stock after buying an additional 2,846 shares during
Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high?
The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.
Four Nasdaq payers hit their ex-dividend dates within two trading days, and one wrong move on timing forfeits the check. Which ones have the cash flow to keep paying, and where does hidden risk lurk behind the yield?
10Elms LLP reduced its position in Amgen Inc. (NASDAQ: AMGN) by 85.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 864 shares of the medical research company's stock after selling 5,000 shares during the quarter. 10Elms
Allworth Financial LP raised its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 2.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,440 shares of the medical research company's stock after purchasing an additional 1,582 shares during the quarter.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.